Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID 19 anti CD40 CoV2 vaccine - EnnoDC

Next Previous
X
Search
Drug Profile

COVID 19 anti CD40 CoV2 vaccine - EnnoDC

Alternative Names: COVID-19 anti-CD40 CoV2 vaccine; αCD40-RBD vaccine - EnnoDC; αCD40.RBD vaccine - EnnoDC

Latest Information Update: 08 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccine Research Institute
  • Developer EnnoDC
  • Class COVID-19 vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 26 Sep 2024 LinKinVax is now called EnnoDC
  • 19 Feb 2023 Immunogenicity data from a preclinical trial in COVID-2019 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
  • 19 Aug 2022 LinKinVax plans a phase I/II trial for COVID-2019 infections (Prevention) in Q4 of 2022 (LinKinVax pipeline, August 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top